Kisqali is a drug used for metastatic breast cancer. In September 2024, the FDA approved it for use in patients with stage 2 or 3 breast cancer that is HR-positive, HER2-negative to decrease the chances that the cancer will return. You can read more here: https://www.nbcnews.com/health/cancer/breast-cancer-treatment-drug-kisqali-approval-expanded-earlier-stage-d-rcna170632.
